Shots:
- Roche has signed a purchase agreement to acquire 100% of the outstanding shares of the TIB. The transaction is expected to close in Q4’21
- The acquisition will bolster Roche’s PCR test portfolio of molecular diagnostics solutions with the addition of multiple assays for infectious disease
- TIB Molbiol currently has 45+ CE-IVD marked tests and 100+ research use assays that are available on Roche’s LightCycler PCR and MagNA Pure sample preparation systems
Click here to read full press release/ article | Ref: Globe Newswire | Image: PharmaLive
The post Roche to Acquire TIB Molbiol for Bolstering its Molecular Diagnostics Portfolio first appeared on PharmaShots.
